ALB-408

ALB-408 is a synthetic peptide developed by Pharis Biotec that functions as an antagonist of the C-X-C chemokine receptor type 4 (CXCR4). It is an optimized derivative of the endogenous peptide EPI-X4, which is a fragment of human serum albumin (residues 408-423) naturally found in human blood. ALB-408 works by binding to and blocking the CXCR4 co-receptor, which is essential for the entry of X4-tropic HIV-1 strains into target CD4+ T lymphocytes. By preventing the interaction between the viral envelope glycoprotein gp120 and the host cell receptor, ALB-408 acts as an entry inhibitor, thereby reducing viral fusion and replication. The drug has been investigated in early-stage clinical settings for the treatment of HIV infections, particularly to target viral variants that utilize the CXCR4 receptor for cellular entry.

Other names

EPI-X4 derivativeEPI-X-4 derivativeEPI-X 4 derivativeoptimized EPI-X4